Tag Archive for: HER2-low breast cancer

The rush to use AstraZeneca and Daiichi-Sankyo’s drug Enhertu to treat certain types of breast cancer has far outpaced doctors’ ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.

AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.

AstraZeneca and Daiichi Sankyo’s Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy, according to data presented on Sunday.